Side-by-side · Research reference
EpitalonvsGHRP-2
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticDraft8/37 cited
BPhase 2Reviewed15/42 cited
Epitalon
Pineal bioregulator · Telomerase activator
SQ or IM · Abdomen · Daily for 10–20 days
GHRP-2
Hexapeptide GHRP · Phase 2 (clinical diagnostic)
SQ · Multiple sites · 1–3×/day
01Mechanism of Action
Parameter
Epitalon
GHRP-2
Primary target
Telomerase activity (proposed); pineal melatonin axis modulationKhavinson 2003
Ghrelin receptor (GHS-R1a) on anterior pituitaryBowers 1990
Pathway
Activation of telomerase reverse transcriptase (hTERT) in somatic cells; pineal-axis modulation supports endogenous melatoninKhavinson 2003
GHS-R1a → Gαq → Ca²⁺ → GH vesicle exocytosisBowers 2002
Downstream effect
Telomere elongation, improved sleep architecture, reported lifespan extension in aged miceKhavinson 2003
Strong GH pulse + IGF-1 elevation; appetite increase via ghrelin agonismBowers 2002
Feedback intact?
—
Yes, with somatostatin feedback active
Origin
Synthetic 4-AA peptide derived from epithalamin (a natural pineal extract)Khavinson 2003
Synthetic hexapeptide; developed by Bowers/Tulane group in the 1980sBowers 1990
Antibody development
—
—
02Dosage Protocols
Parameter
Epitalon
GHRP-2
Standard dose
5–10 mg / day for 10–20 days, 1–2× per yearKhavinson 2003
Anecdotal community protocol. Russian clinical literature uses similar cycling.
100–300 mcg per injectionBowers 1990
Frequency
Once daily during a cycle
1–3× per day
Lower / starter dose
2.5 mg / day
50 mcg per dose
Evidence basis
In-vitro telomerase + Russian clinical trialsKhavinson 2003
Phase 2 + clinical diagnostic useBowers 1990
Duration
10–20 day cycles, 1–2× per year
8–12 weeks on / 4 off (anecdotal)
Reconstitution
Bacteriostatic water
Bacteriostatic water
Timing
Pre-sleep preferred (pineal alignment)
Pre-sleep + fasted preferred
04Side Effects & Safety
Parameter
Epitalon
GHRP-2
Injection site reaction
Mild irritation
Mild erythema
Sleep architecture
Improved subjective sleep quality (anecdotal)
—
Cancer risk
Theoretical via telomerase activation in pre-malignant cells
Contraindicated in active malignancy
Long-term safety
Limited Western RCT data
—
Pregnancy / OB
Avoid
Avoid
Antibody formation
Not reported
—
Prolactin elevation
—
Mild but measurable
Hunger
—
Strong appetite increase
IGF-1 elevation
—
Strong; monitor with chronic high-dose use
Absolute Contraindications
Epitalon
- ·Pregnancy / breastfeeding
- ·Active malignancy or pre-malignant state
GHRP-2
- ·Active malignancy
- ·Pregnancy / breastfeeding
Relative Contraindications
Epitalon
- ·Family history of cancer
GHRP-2
- ·Untreated diabetes
05Administration Protocol
Parameter
Epitalon
GHRP-2
1. Reconstitution
Add 1–2 mL bacteriostatic water to 10 mg vial → 5–10 mg/mL.
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.
2. Injection site
SQ — abdomen preferred. Rotate sites.
SQ — abdomen or thigh. Rotate sites.
3. Timing
Pre-sleep preferred to align with pineal axis.
Pre-sleep + fasted preferred.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
5. Needle
29–31G, 4–8 mm insulin syringe.
29–31G, 4–8 mm insulin syringe.
06Stack Synergy
Epitalon
— no documented stacks
GHRP-2
+ CJC-1295 (no DAC)
StrongGHRP-2 + CJC-1295-no-DAC is a higher-amplitude alternative to the ipamorelin + CJC-1295 stack. GHRP-2 produces a stronger pulse but with cortisol + prolactin signal — choose when maximum GH amplitude is the goal and the side-effect tolerance is acceptable.
- GHRP-2
- 100–200 mcg SQ · pre-sleep
- CJC-1295 (no DAC)
- 100 mcg SQ · same injection
- Primary benefit
- High-amplitude GH pulse, body composition